|
|
News Breaks | | | | January 2, 2013 | | 13:01 EDT |  | AMRN | Amarin volatility at low end of historic range
Amarin January call option implied volatility is at 73, February is at 77, March is at 81; below its 26-week average of 101 according to Track Data, suggesting decreasing price movement. | |
|
News For AMRN From The Last 14 Days Check below for free stories on AMRN the last two weeks. |
|
|
| May 17, 2013 | | 14:12 EDT |  | AMRN | Amarin shares slip after FDA updates Orange Book
 Subscribe for More Information | | | May 15, 2013 | | 11:04 EDT |  | AMRN | Amarin management to meet with Lazard Capital
Meeting to be held in the Mid-Atlantic area on May 16 hosted by Lazard Capital. | | | May 13, 2013 | | 12:52 EDT | | AMRN | Amarin strength attributed to MassHealth drug list addition
Subscribe for More Information | | | May 10, 2013 | | 09:23 EDT |  | AMRN | Amarin continues to make progress with payors, says Leerink
Leerink reiterates an Outperform rating on shares of Amarin following the company's Q1 results. The firm believes Amarin continues to make good progress with payors and that Vascepa script trends are tracking well. | | | May 9, 2013 | | 16:18 EDT |  | AMRN | Amarin reports Q1 EPS (41c), consensus (39c)
Reports Q1 revenue $2.34M, consensus $5.2M. Amarin said its direct sales force, consisting of approximately 275 sales professionals, made sales calls to clinicians for two months in Q1. Amarin reports that, since launch, access to clinicians has been good, and that it has yet to hear any significant negative reaction to the efficacy or safety profile of Vascepa. Amarin said it continues to make significant progress in its effort to expand patent protection for Vascepa and now has 22 patents issued or allowed in the United States with over 30 additional U.S. patent applications being prosecuted. | | | 13:15 EDT | | AMRN | Amarin, Omthera drop following fatty acids study in journal
Subscribe for More Information | |
|
|
|
|
|
|
